Aspire Private Capital’s Lexaria Bioscience LEXX Stock Holding History

Aspire Private Capital’s Portfolio LEXX Stock Details LEXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-400	Closed	-$1.22K	–	431
2024 Q3	$1.22K	Hold	400	–	–	﹤0.01%	583
2024 Q2	$1.11K	Hold	400	–	–	﹤0.01%	592
2024 Q1	$1.45K	Hold	400	–	–	﹤0.01%	603
2023 Q4	$500	Hold	400	–	–	﹤0.01%	644
2023 Q3	$399	Hold	400	–	–	﹤0.01%	646
2023 Q2	$292	Hold	400	–	–	﹤0.01%	629
2023 Q1	$1.09K	Hold	400	–	–	﹤0.01%	566
2022 Q4	$984	Hold	400	–	–	﹤0.01%	562
2022 Q3	$1K	Hold	400	–	–	﹤0.01%	573
2022 Q2	$1K	Hold	400	–	–	﹤0.01%	557
2022 Q1	$1K	Hold	400	–	–	﹤0.01%	555
2021 Q4	$2K	Buy	+400	New	+$2.28K	﹤0.01%	526

Other funds holding LEXX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Aspire Private Capital's LEXX Position: Q4 2024 in Review

Aspire Private Capital sold out of Lexaria Bioscience (LEXX) in Q4 2024, closing a stake of 400 shares — an estimated $1.22K sold.

Aspire Private Capital first reported a position in LEXX in Q4 2021 and held it in 12 quarters. The position peaked at $2K in Q4 2021. 25 funds tracked by Wall St. Rank hold LEXX as of Q4 2024.

Aspire Private Capital reported no remaining Lexaria Bioscience position as of Q4 2024 after selling out during the quarter.
Aspire Private Capital sold 400 Lexaria Bioscience shares in Q4 2024, an estimated $1.22K.
Aspire Private Capital first reported a position in Lexaria Bioscience in Q4 2021 and held it in 12 quarters.
Aspire Private Capital's Lexaria Bioscience position peaked at $2K in Q4 2021.
25 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q4 2024.

Based on Aspire Private Capital's 13F filing for Q4 2024, filed 17 Jan 2025.